POPULATION PHARMACOKINETICS OF BRENTUXIMAB VEDOTIN, AN ANTIBODY-DRUG CONJUGATE (ADC), IN PATIENTS WITH CD30-POSITIVE HEMATOLOGIC MALIGNANCIES.

被引：0
|
作者：
Li, H. [1 ]
Han, T. H. [2 ]
Hunder, N. [1 ]
Jang, G. [1 ]
Zhao, B. [1 ]
机构：
[1] Seattle Genet, Bothell, WA USA
[2] Stemcentrx Inc, San Francisco, CA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-041
引用
收藏
页码：S41 / S42
页数：2
相关论文
共 50 条
  • [41] Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate
    Costa, Philippos Apolinario
    Espejo-Freire, Andrea Patricia
    Fan, Kenneth Chen
    Albini, Thomas Arno
    Pongas, Georgios
    LEUKEMIA & LYMPHOMA, 2022, 63 (01) : 239 - 242
  • [42] Extravasation of brentuximab vedotin, an antibody-drug conjugate, in a patient with anaplastic large cell lymphoma
    Rivasi, Marianna
    Porretta Serapiglia, Carla
    Medici, Gregorio
    Ricchi, Lucia
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2024,
  • [43] SGN-35, an anti-CD30 antibody-drug conjugate, exhibits potent antitumor activity for the treatment of CD30+ malignancies.
    Hamblett, KJ
    Barton, J
    Cerveny, CG
    Andreyka, JB
    Kissler, KM
    Okeley, NM
    Stone, I
    Sutherland, MK
    Sun, MM
    Senter, PD
    Wahl, AF
    Ihle, NC
    BLOOD, 2005, 106 (11) : 181A - 181A
  • [44] A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies
    Kim, S. Y.
    Theunissen, J-W
    Balibalos, J.
    Liao-Chan, S.
    Babcock, M. C.
    Wong, T.
    Cairns, B.
    Gonzalez, D.
    van der Horst, E. H.
    Perez, M.
    Levashova, Z.
    Chinn, L.
    D'Alessio, J. A.
    Flory, M.
    Bermudez, A.
    Jackson, D. Y.
    Ha, E.
    Monteon, J.
    Bruhns, M. F.
    Chen, G.
    Migone, T-S
    BLOOD CANCER JOURNAL, 2015, 5 : e316 - e316
  • [45] Advanced-stage CD30-positive mycosis fungoides: Clinical experience with brentuximab vedotin
    Vico-Alonso, Cristina
    Jose Andres-Lencina, Juan
    Aragon-Miguel, Raquel
    Calleja-Algarra, Alba
    Pinilla-Martin, Belen
    Sanchez-Velazquez, Alba
    Munoz-Gonzalez, Hector
    Penalba, Maria
    Velasco Tamariz, Virginia
    Postigo LLorente, Concepcion
    Ortiz-Romero, Pablo L.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB173 - AB173
  • [46] Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study
    Suri, Ajit
    Mould, Diane R.
    Liu, Yi
    Jang, Graham
    Venkatakrishnan, Karthik
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (05) : 989 - 999
  • [47] Sezary Syndrome with Nodal CD30-positive Manifestation Treated with Brentuximab Vedotin and Extracorporeal Photopheresis
    Behle, Valeria
    Von Braunmuehl, Tanja
    Sayehli, Cyrus
    Gesierich, Anja
    Goebeler, Matthias
    Geissinger, Eva
    Wobser, Marion
    ACTA DERMATO-VENEREOLOGICA, 2017, 97 (08) : 973 - 975
  • [48] Antibody-Drug Conjugate Made of Zoledronic Acid and the Anti-CD30 Brentuximab-Vedotin Exert Anti-Lymphoma and Immunostimulating Effects
    Morelli, Feliciana
    Matis, Serena
    Benelli, Roberto
    Salvini, Laura
    Zocchi, Maria Raffaella
    Poggi, Alessandro
    CELLS, 2024, 13 (10)
  • [49] PERSISTENCE OF CD30 EXPRESSION IN CD30-POSITIVE LYMPHOMAS FOLLOWING TREATMENT WITH BRENTUXIMAB VEDOTIN (SGN-35)
    Chen, W.
    Nathwani, N.
    Forman, S.
    Popplewell, L.
    Krishnan, A.
    Gomez, C.
    Karanes, C.
    Smith, E.
    Farol, L.
    Thomas, S.
    Kim, Y.
    HAEMATOLOGICA, 2012, 97 : 81 - 82
  • [50] A Novel Antibody-Drug Conjugate Targeting CCR7 in Hematologic Malignancies
    Dang, Anhthu
    Knee, Deborah
    Wang, Cui Ying
    Gao, Feng
    Liu, Guoxun
    Briones, Sergio
    Coulson, Michelle
    Makofske, Jessica
    Mansfield, Keith
    Liu, May
    Mulvey, Tanya
    Meseck, Emily K.
    Woolfenden, Steve
    Buchanan, Sean G.
    Steensma, David
    Askoxylakis, Vasileios
    BLOOD, 2022, 140 : 11564 - 11565
12345